Novo Nordisk Offers Discounted Wegovy Subscriptions for U.S. Self-Pay Patients

• Wegovy subscriptions range from $249-$329 monthly (6-29% discount) depending on commitment length, while Lilly's Zepbound starts at $299/month for lower doses
• The move follows Novo's November 2024 price cut from $499 to $349 monthly and represents a strategic pivot to telehealth partnerships with Ro, WeightWatchers, and LifeMD
• Both drugmakers are competing to steer patients from cheaper compounded copies to FDA-approved branded drugs while adapting to patients becoming 'consumers of health' who pay out-of-pocket

Novo Nordisk Launches Discounted Wegovy Subscriptions in U.S. Market

Key Development:

Novo Nordisk announced a new subscription program offering Wegovy weight-loss medication at discounts of up to 29% for U.S. self-pay patients, launching Tuesday through telehealth platforms including Ro, WeightWatchers, and LifeMD.

Pricing Details:

• Wegovy injection pens: $249-$329 monthly depending on subscription length (3, 6, or 12 months), compared to standard $349/month
• Wegovy pill: $249-$289 monthly versus standard $299/month
• Competitor Eli Lilly's Zepbound: $299-$449 monthly depending on dosage

Market Context:

This marks Novo's second major price cut after reducing standard monthly self-pay prices from $499 to $349 in November 2023—a roughly 30% reduction. The move comes as Novo attempts to regain market share from Eli Lilly, whose Zepbound prescriptions have outpaced Wegovy. Analysts warn Novo risks being on the losing end of an intensifying price war.

Strategic Shift:

The obesity drug market is transitioning to a consumer-focused model, with both Novo and Lilly bypassing traditional insurance channels and doctors' offices. Companies are leveraging direct-to-consumer sales through telehealth platforms to retain patients, improve adherence, and divert them from cheaper compounded alternatives.

Competitive Landscape:

Novo restructured its commercial operations and appointed new U.S. leadership last year to better compete with Lilly, which moved more quickly into direct sales. Lilly's oral obesity drug is under FDA review with expected approval in Q2 2026.

Market Implications:

The aggressive pricing strategy threatens profit margins but reflects broader competitive pressure in the booming obesity drug market, where patient retention and market share increasingly depend on affordability and accessibility.